ENTvantage Dx Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.14M

  • Investors
  • 13

ENTvantage Dx General Information

Description

Manufacturer of in-office diagnostic test kits intended to determine the cause of ear, nose, and throat illnesses. The company's product qualitatively identifies the major bacterial sinusitis pathogens and provides differentiation from viral sinusitis infections, enabling physicians to only prescribe antibiotic treatment for patients who have bacterial sinusitis, reducing the unnecessary prescription of antibiotics.

Contact Information

Website
www.entvantagedx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Primary Office
  • 4200 Marathon Boulevard
  • Suite 200
  • Austin, TX 78756
  • United States
+1 (800) 000-0000

ENTvantage Dx Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ENTvantage Dx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 20-Jan-2021 $1.14M 00.000 Completed Generating Revenue
9. Grant 01-Feb-2020 00000 00.000 Completed Generating Revenue
8. Later Stage VC 20-Aug-2019 00000 00.000 Completed Generating Revenue
7. Later Stage VC 01-Oct-2018 0000 00.000 Completed Generating Revenue
6. Early Stage VC (Series B) 03-Nov-2017 00.00 00.000 000.00 Completed Generating Revenue
5. Early Stage VC (Series A) 01-Oct-2016 00.000 00.000 000.00 Completed Generating Revenue
4. Grant 14-Jan-2016 0000 Completed Generating Revenue
3. Accelerator/Incubator 10-Dec-2014 Completed Generating Revenue
2. Grant 02-Apr-2014 $1K Completed Generating Revenue
1. Early Stage VC 01-Jan-2014 Completed Startup
To view ENTvantage Dx’s complete valuation and funding history, request access »

ENTvantage Dx Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 000,000 00 00.00 00.00 00 00.00 00.000
Series A 000,000 00 00.00 00.00 00 00.00 00.000
To view ENTvantage Dx’s complete cap table history, request access »

ENTvantage Dx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Manufacturer of in-office diagnostic test kits intended to determine the cause of ear, nose, and throat illnesses. The c
Diagnostic Equipment
Austin, TX
6 As of 2023
00.000
0000000000 0 00.000

0-0000

illum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non pro
0000000000 000000000
Uppsala, Sweden
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ENTvantage Dx Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
0-00000 Formerly VC-backed Uppsala, Sweden 000 00000 00000000 00000
You’re viewing 1 of 1 competitors. Get the full list »

ENTvantage Dx Patents

  • 19

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

ENTvantage Dx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018244352-A1 Devices and methods for diagnosis of sinusitis Inactive 28-Mar-2017 00000000000
CA-3057853-A1 Devices and methods for diagnosis of sinusitis Pending 28-Mar-2017 00000000000
EP-3600066-A1 Devices and methods for diagnosis of sinusitis Pending 28-Mar-2017 00000000000
EP-3600066-A4 Devices and methods for diagnosis of sinusitis Pending 28-Mar-2017 00000000000 0
JP-2020515365-A Sinusitis diagnostic device and method Pending 28-Mar-2017 A61B10/0045 0
To view ENTvantage Dx’s complete patent history, request access »

ENTvantage Dx Executive Team (2)

Name Title Board Seat Contact Info
Joseph Skraba President & Chief Executive Officer
You’re viewing 1 of 2 executive team members. Get the full list »

ENTvantage Dx Board Members (5)

Name Representing Role Since
Blobel Friedhelm ENTvantage Dx Board Member 000 0000
Donald Gonzales MD Self Board Member 000 0000
John Paulos ENTvantage Dx Board Member 000 0000
Richard Hawkins Self Chairman 000 0000
Russell Bradley Self Board Member 000 0000
To view ENTvantage Dx’s complete board members history, request access »

ENTvantage Dx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ENTvantage Dx Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Capital Factory Venture Capital Minority 000 0000 000000 0
Denniston Family Office Family Office Minority 000 0000 000000 0
Sea Purity Investments Family Office Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
Supernode Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial